+1 (704) 266-3234

Global Urological Cancer Drugs Market Size, Status And Forecast 2019-2025

Published on: Jun 2019 | From USD $3900 | Published By: QY RESEARCH | Number Of Pages: 106

In 2018, the global Urological Cancer Drugs market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025.

This report focuses on the global Urological Cancer Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Urological Cancer Drugs development in United States, Europe and China.

The key players covered in this study
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A
Tolmar Inc

Market segment by Type, the product can be split into
Tablets
Injection

Market segment by Application, split into
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Other

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Urological Cancer Drugs status, future forecast, growth opportunity, key market and key players.
To present the Urological Cancer Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Urological Cancer Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Urological Cancer Drugs Market Size Growth Rate by Type (2014-2025)
1.4.2 Tablets
1.4.3 Injection
1.5 Market by Application
1.5.1 Global Urological Cancer Drugs Market Share by Application (2014-2025)
1.5.2 Prostate Cancer
1.5.3 Bladder Cancer
1.5.4 Kidney Cancer
1.5.5 Testicular Cancer
1.5.6 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Urological Cancer Drugs Market Size
2.2 Urological Cancer Drugs Growth Trends by Regions
2.2.1 Urological Cancer Drugs Market Size by Regions (2014-2025)
2.2.2 Urological Cancer Drugs Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Urological Cancer Drugs Market Size by Manufacturers
3.1.1 Global Urological Cancer Drugs Revenue by Manufacturers (2014-2019)
3.1.2 Global Urological Cancer Drugs Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Urological Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Urological Cancer Drugs Key Players Head office and Area Served
3.3 Key Players Urological Cancer Drugs Product/Solution/Service
3.4 Date of Enter into Urological Cancer Drugs Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Urological Cancer Drugs Market Size by Type (2014-2019)
4.2 Global Urological Cancer Drugs Market Size by Application (2014-2019)

5 United States
5.1 United States Urological Cancer Drugs Market Size (2014-2019)
5.2 Urological Cancer Drugs Key Players in United States
5.3 United States Urological Cancer Drugs Market Size by Type
5.4 United States Urological Cancer Drugs Market Size by Application

6 Europe
6.1 Europe Urological Cancer Drugs Market Size (2014-2019)
6.2 Urological Cancer Drugs Key Players in Europe
6.3 Europe Urological Cancer Drugs Market Size by Type
6.4 Europe Urological Cancer Drugs Market Size by Application

7 China
7.1 China Urological Cancer Drugs Market Size (2014-2019)
7.2 Urological Cancer Drugs Key Players in China
7.3 China Urological Cancer Drugs Market Size by Type
7.4 China Urological Cancer Drugs Market Size by Application

8 Japan
8.1 Japan Urological Cancer Drugs Market Size (2014-2019)
8.2 Urological Cancer Drugs Key Players in Japan
8.3 Japan Urological Cancer Drugs Market Size by Type
8.4 Japan Urological Cancer Drugs Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Urological Cancer Drugs Market Size (2014-2019)
9.2 Urological Cancer Drugs Key Players in Southeast Asia
9.3 Southeast Asia Urological Cancer Drugs Market Size by Type
9.4 Southeast Asia Urological Cancer Drugs Market Size by Application

10 India
10.1 India Urological Cancer Drugs Market Size (2014-2019)
10.2 Urological Cancer Drugs Key Players in India
10.3 India Urological Cancer Drugs Market Size by Type
10.4 India Urological Cancer Drugs Market Size by Application

11 Central & South America
11.1 Central & South America Urological Cancer Drugs Market Size (2014-2019)
11.2 Urological Cancer Drugs Key Players in Central & South America
11.3 Central & South America Urological Cancer Drugs Market Size by Type
11.4 Central & South America Urological Cancer Drugs Market Size by Application

12 International Players Profiles
12.1 Novartis
12.1.1 Novartis Company Details
12.1.2 Company Description and Business Overview
12.1.3 Urological Cancer Drugs Introduction
12.1.4 Novartis Revenue in Urological Cancer Drugs Business (2014-2019)
12.1.5 Novartis Recent Development
12.2 Pfizer
12.2.1 Pfizer Company Details
12.2.2 Company Description and Business Overview
12.2.3 Urological Cancer Drugs Introduction
12.2.4 Pfizer Revenue in Urological Cancer Drugs Business (2014-2019)
12.2.5 Pfizer Recent Development
12.3 Johnson & Johnson
12.3.1 Johnson & Johnson Company Details
12.3.2 Company Description and Business Overview
12.3.3 Urological Cancer Drugs Introduction
12.3.4 Johnson & Johnson Revenue in Urological Cancer Drugs Business (2014-2019)
12.3.5 Johnson & Johnson Recent Development
12.4 AstraZeneca
12.4.1 AstraZeneca Company Details
12.4.2 Company Description and Business Overview
12.4.3 Urological Cancer Drugs Introduction
12.4.4 AstraZeneca Revenue in Urological Cancer Drugs Business (2014-2019)
12.4.5 AstraZeneca Recent Development
12.5 Astellas
12.5.1 Astellas Company Details
12.5.2 Company Description and Business Overview
12.5.3 Urological Cancer Drugs Introduction
12.5.4 Astellas Revenue in Urological Cancer Drugs Business (2014-2019)
12.5.5 Astellas Recent Development
12.6 Bristol-Myers Squibb
12.6.1 Bristol-Myers Squibb Company Details
12.6.2 Company Description and Business Overview
12.6.3 Urological Cancer Drugs Introduction
12.6.4 Bristol-Myers Squibb Revenue in Urological Cancer Drugs Business (2014-2019)
12.6.5 Bristol-Myers Squibb Recent Development
12.7 Abbott Laboratories
12.7.1 Abbott Laboratories Company Details
12.7.2 Company Description and Business Overview
12.7.3 Urological Cancer Drugs Introduction
12.7.4 Abbott Laboratories Revenue in Urological Cancer Drugs Business (2014-2019)
12.7.5 Abbott Laboratories Recent Development
12.8 Celgene Corporation
12.8.1 Celgene Corporation Company Details
12.8.2 Company Description and Business Overview
12.8.3 Urological Cancer Drugs Introduction
12.8.4 Celgene Corporation Revenue in Urological Cancer Drugs Business (2014-2019)
12.8.5 Celgene Corporation Recent Development
12.9 Dendreon Corporation
12.9.1 Dendreon Corporation Company Details
12.9.2 Company Description and Business Overview
12.9.3 Urological Cancer Drugs Introduction
12.9.4 Dendreon Corporation Revenue in Urological Cancer Drugs Business (2014-2019)
12.9.5 Dendreon Corporation Recent Development
12.10 Ferring Pharmaceuticals
12.10.1 Ferring Pharmaceuticals Company Details
12.10.2 Company Description and Business Overview
12.10.3 Urological Cancer Drugs Introduction
12.10.4 Ferring Pharmaceuticals Revenue in Urological Cancer Drugs Business (2014-2019)
12.10.5 Ferring Pharmaceuticals Recent Development
12.11 GlaxoSmithKline
12.12 Indevus Pharmaceuticals Inc
12.13 Ipsen
12.14 Roche Healthcare
12.15 Sanofi S.A
12.16 Tolmar Inc

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

List of Tables and Figures

Table Urological Cancer Drugs Key Market Segments
Table Key Players Urological Cancer Drugs Covered
Table Global Urological Cancer Drugs Market Size Growth Rate by Type 2014-2025 (Million US$)
Figure Global Urological Cancer Drugs Market Size Market Share by Type 2014-2025
Figure Tablets Figures
Table Key Players of Tablets
Figure Injection Figures
Table Key Players of Injection
Table Global Urological Cancer Drugs Market Size Growth by Application 2014-2025 (Million US$)
Figure Prostate Cancer Case Studies
Figure Bladder Cancer Case Studies
Figure Kidney Cancer Case Studies
Figure Testicular Cancer Case Studies
Figure Other Case Studies
Figure Urological Cancer Drugs Report Years Considered
Table Global Urological Cancer Drugs Market Size 2014-2025 (Million US$)
Figure Global Urological Cancer Drugs Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Urological Cancer Drugs Market Size by Regions 2014-2025 (Million US$)
Table Global Urological Cancer Drugs Market Size by Regions 2014-2019 (Million US$)
Table Global Urological Cancer Drugs Market Share by Regions 2014-2019
Figure Global Urological Cancer Drugs Market Share by Regions 2014-2019
Figure Global Urological Cancer Drugs Market Share by Regions 2019
Table Market Top Trends
Table Global Urological Cancer Drugs Revenue by Manufacturers (2014-2019) (Million US$)
Table Global Urological Cancer Drugs Market Share by Manufacturers (2014-2019)
Figure Global Urological Cancer Drugs Market Share by Manufacturers in 2018
Table Global Urological Cancer Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Urological Cancer Drugs Product/Solution/Service
Table Date of Enter into Urological Cancer Drugs Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Urological Cancer Drugs Market Size by Type (2014-2019) (Million US$)
Table Global Urological Cancer Drugs Market Size Share by Type (2014-2019)
Figure Global Urological Cancer Drugs Market Size Market Share by Type (2014-2019)
Table Global Urological Cancer Drugs Market Size by Application (2014-2019) (Million US$)
Table Global Urological Cancer Drugs Market Size Share by Application (2014-2019)
Figure Global Urological Cancer Drugs Market Size Market Share by Application (2014-2019)
Figure Global Urological Cancer Drugs Revenue Market Share by Application in 2018
Figure United States Urological Cancer Drugs Market Size 2014-2019 (Million US$)
Table United States Key Players Urological Cancer Drugs Revenue (2018-2019) (Million US$)
Table United States Key Players Urological Cancer Drugs Market Share (2018-2019)
Table United States Urological Cancer Drugs Market Size by Type (2014-2019) (Million US$)
Table United States Urological Cancer Drugs Market Share by Type (2014-2019)
Table United States Urological Cancer Drugs Market Size by Application (2014-2019) (Million US$)
Table United States Urological Cancer Drugs Market Share by Application (2014-2019)
Figure Europe Urological Cancer Drugs Market Size 2014-2019 (Million US$)
Table Europe Key Players Urological Cancer Drugs Revenue (2018-2019) (Million US$)
Table Europe Key Players Urological Cancer Drugs Market Share (2018-2019)
Table Europe Urological Cancer Drugs Market Size by Type (2014-2019) (Million US$)
Table Europe Urological Cancer Drugs Market Share by Type (2014-2019)
Table Europe Urological Cancer Drugs Market Size by Application (2014-2019) (Million US$)
Table Europe Urological Cancer Drugs Market Share by Application (2014-2019)
Figure China Urological Cancer Drugs Market Size 2014-2019 (Million US$)
Table China Key Players Urological Cancer Drugs Revenue (2018-2019) (Million US$)
Table China Key Players Urological Cancer Drugs Market Share (2018-2019)
Table China Urological Cancer Drugs Market Size by Type (2014-20189) (Million US$)
Table China Urological Cancer Drugs Market Share by Type (2014-2019)
Table China Urological Cancer Drugs Market Size by Application (2014-2019) (Million US$)
Table China Urological Cancer Drugs Market Share by Application (2014-2019)
Figure Japan Urological Cancer Drugs Market Size 2014-2019 (Million US$)
Table Japan Key Players Urological Cancer Drugs Revenue (2018-2019) (Million US$)
Table Japan Key Players Urological Cancer Drugs Market Share (2018-2019)
Table Japan Urological Cancer Drugs Market Size by Type (2014-2019) (Million US$)
Table Japan Urological Cancer Drugs Market Share by Type (2014-2019)
Table Japan Urological Cancer Drugs Market Size by Application (2014-2019) (Million US$)
Table Japan Urological Cancer Drugs Market Share by Application (2014-2019)
Figure Southeast Asia Urological Cancer Drugs Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Urological Cancer Drugs Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Urological Cancer Drugs Market Share (2018-2019)
Table Southeast Asia Urological Cancer Drugs Market Size by Type (2014-2019) (Million US$)
Table Southeast Asia Urological Cancer Drugs Market Share by Type (2014-2019)
Table Southeast Asia Urological Cancer Drugs Market Size by Application (2014-2019) (Million US$)
Table Southeast Asia Urological Cancer Drugs Market Share by Application (2014-2019)
Figure India Urological Cancer Drugs Market Size 2014-2019 (Million US$)
Table India Key Players Urological Cancer Drugs Revenue (2018-2019) (Million US$)
Table India Key Players Urological Cancer Drugs Market Share (2018-2019)
Table India Urological Cancer Drugs Market Size by Type (2014-2019) (Million US$)
Table India Urological Cancer Drugs Market Share by Type (2014-2019)
Table India Urological Cancer Drugs Market Size by Application (2014-2019) (Million US$)
Table India Urological Cancer Drugs Market Share by Application (2014-2019)
Figure Central & South America Urological Cancer Drugs Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Urological Cancer Drugs Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Urological Cancer Drugs Market Share (2018-2019)
Table Central & South America Urological Cancer Drugs Market Size by Type (2014-2019) (Million US$)
Table Central & South America Urological Cancer Drugs Market Share by Type (2014-2019)
Table Central & South America Urological Cancer Drugs Market Size by Application (2014-2019) (Million US$)
Table Central & South America Urological Cancer Drugs Market Share by Application (2014-2019)
Table Novartis Company Details
Table Novartis Revenue in Urological Cancer Drugs Business (2014-2019) (Million US$)
Figure Novartis Revenue Growth Rate in Urological Cancer Drugs Business (2014-2019)
Table Novartis Recent Development
Table Pfizer Company Details
Table Pfizer Revenue in Urological Cancer Drugs Business (2014-2019)(Million US$)
Figure Pfizer Revenue Growth Rate in Urological Cancer Drugs Business (2014-2019)
Table Pfizer Recent Development
Table Johnson & Johnson Company Details
Table Johnson & Johnson Revenue in Urological Cancer Drugs Business (2014-2019)(Million US$)
Figure Johnson & Johnson Revenue Growth Rate in Urological Cancer Drugs Business (2014-2019)
Table Johnson & Johnson Recent Development
Table AstraZeneca Company Details
Table AstraZeneca Revenue in Urological Cancer Drugs Business (2014-2019)(Million US$)
Figure AstraZeneca Revenue Growth Rate in Urological Cancer Drugs Business (2014-2019)
Table AstraZeneca Recent Development
Table Astellas Company Details
Table Astellas Revenue in Urological Cancer Drugs Business (2014-2019)(Million US$)
Figure Astellas Revenue Growth Rate in Urological Cancer Drugs Business (2014-2019)
Table Astellas Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Revenue in Urological Cancer Drugs Business (2014-2019)(Million US$)
Figure Bristol-Myers Squibb Revenue Growth Rate in Urological Cancer Drugs Business (2014-2019)
Table Bristol-Myers Squibb Recent Development
Table Abbott Laboratories Company Details
Table Abbott Laboratories Revenue in Urological Cancer Drugs Business (2014-2019)(Million US$)
Figure Abbott Laboratories Revenue Growth Rate in Urological Cancer Drugs Business (2014-2019)
Table Abbott Laboratories Recent Development
Table Celgene Corporation Company Details
Table Celgene Corporation Revenue in Urological Cancer Drugs Business (2014-2019)(Million US$)
Figure Celgene Corporation Revenue Growth Rate in Urological Cancer Drugs Business (2014-2019)
Table Celgene Corporation Recent Development
Table Dendreon Corporation Company Details
Table Dendreon Corporation Revenue in Urological Cancer Drugs Business (2014-2019)(Million US$)
Figure Dendreon Corporation Revenue Growth Rate in Urological Cancer Drugs Business (2014-2019)
Table Dendreon Corporation Recent Development
Table Ferring Pharmaceuticals Company Details
Table Ferring Pharmaceuticals Revenue in Urological Cancer Drugs Business (2014-2019)(Million US$)
Figure Ferring Pharmaceuticals Revenue Growth Rate in Urological Cancer Drugs Business (2014-2019)
Table Ferring Pharmaceuticals Recent Development
Table GlaxoSmithKline Company Details
Table Indevus Pharmaceuticals Inc Company Details
Table Ipsen Company Details
Table Roche Healthcare Company Details
Table Sanofi S.A Company Details
Table Tolmar Inc Company Details
Table Global Urological Cancer Drugs Market Size by Regions (Million US$) 2019-2025
Figure Global Urological Cancer Drugs Market Size Share by Regions (2019-2025)
Figure Global Urological Cancer Drugs Market Size Share by Regions in 2025
Figure United States Urological Cancer Drugs Market Size Forecast (2019-2025)(Million USD)
Figure Europe Urological Cancer Drugs Market Size Forecast (2019-2025)(Million USD)
Figure China Urological Cancer Drugs Market Size Forecast (2019-2025)(Million USD)
Figure Japan Urological Cancer Drugs Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Urological Cancer Drugs Market Size Forecast (2019-2025)(Million USD)
Figure India Urological Cancer Drugs Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Urological Cancer Drugs Market Size Forecast (2019-2025)(Million USD)
Table Global Urological Cancer Drugs Market Size by Product (2019-2025) (Million US$)
Figure Global Urological Cancer Drugs Market Size by Product (2019-2025)
Figure Global Urological Cancer Drugs Market Size by Product in 2025
Table Global Urological Cancer Drugs Market Size by Application (2019-2025) (Million US$)
Figure Global Urological Cancer Drugs Market Size by Application (2019-2025)
Figure Global Urological Cancer Drugs Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $3900
USD $5850
USD $7800
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.